TTC-352 is an orally bioavailable selective human estrogen receptor alpha (ERalpha, ESR1, ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells.
Molekulargewicht:
352.38
CAS Nummer:
[1607819-68-0]
Formel:
C20H13FO3S
Target-Kategorie:
Estrogen Receptor/ERR|||Others
T70399
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
